To validate the in vivo impact of CHOP on the anticancer effect of Regorafenib, a xenograft tumor model was established using HCC-LM3 cells and then transfected with oe-NC or oe-CHOP, followed by intervention with either vehicle or Regorafenib. The gene discussed is DDIT3; the disease is neoplasm.